Clinical involvement and protein expression in individuals with the FMR1 premutation

Flora Tassone, Randi J Hagerman, A. K. Taylor, J. B. Mills, S. W. Harris, L. W. Gane, Paul J Hagerman

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Most individuals with the fragile X premutation are clinically unaffected; however, some show clinical manifestations, including learning difficulties, emotional problems, or even mental retardation. The basis of clinical involvement in these individuals is unknown. Premutation alleles are reportedly associated with normal levels of mRNA and protein (FMRP). To examine this issue in more detail, we studied six individuals with a premutation. We are reporting these cases to demonstrate a spectrum of phenotypic involvement which can be seen clinically. These cases include one individual with the premutation who has no evidence of FMR1 gene dysfunction but has mental retardation from other causes. Other cases presented here show varying degrees of FMR1 gene dysfunction as assessed by FMRP and FMR1 mRNA levels and various clinical features of fragile X. In two cases we observed a significant reduction in FMRP expression and an elevated FMR1 mRNA expression level associated with moderate cognitive deficit. Thus, the utilization of FMRP measures can be helpful in understanding for which premutation patients clinical involvement is caused by dysfunction of the FMR1 gene. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)144-152
Number of pages9
JournalAmerican Journal of Medical Genetics
Volume91
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Intellectual Disability
Messenger RNA
Fragile X Mental Retardation Protein
Genes
Proteins
Alleles
Learning

Keywords

  • FMRP
  • Fragile X syndrome
  • Immunocytochemistry
  • Mental retardation
  • Trinucleotide repeat

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Clinical involvement and protein expression in individuals with the FMR1 premutation. / Tassone, Flora; Hagerman, Randi J; Taylor, A. K.; Mills, J. B.; Harris, S. W.; Gane, L. W.; Hagerman, Paul J.

In: American Journal of Medical Genetics, Vol. 91, No. 2, 2000, p. 144-152.

Research output: Contribution to journalArticle

@article{08bdf4bf6486427d8d936a46578d0d22,
title = "Clinical involvement and protein expression in individuals with the FMR1 premutation",
abstract = "Most individuals with the fragile X premutation are clinically unaffected; however, some show clinical manifestations, including learning difficulties, emotional problems, or even mental retardation. The basis of clinical involvement in these individuals is unknown. Premutation alleles are reportedly associated with normal levels of mRNA and protein (FMRP). To examine this issue in more detail, we studied six individuals with a premutation. We are reporting these cases to demonstrate a spectrum of phenotypic involvement which can be seen clinically. These cases include one individual with the premutation who has no evidence of FMR1 gene dysfunction but has mental retardation from other causes. Other cases presented here show varying degrees of FMR1 gene dysfunction as assessed by FMRP and FMR1 mRNA levels and various clinical features of fragile X. In two cases we observed a significant reduction in FMRP expression and an elevated FMR1 mRNA expression level associated with moderate cognitive deficit. Thus, the utilization of FMRP measures can be helpful in understanding for which premutation patients clinical involvement is caused by dysfunction of the FMR1 gene. (C) 2000 Wiley-Liss, Inc.",
keywords = "FMRP, Fragile X syndrome, Immunocytochemistry, Mental retardation, Trinucleotide repeat",
author = "Flora Tassone and Hagerman, {Randi J} and Taylor, {A. K.} and Mills, {J. B.} and Harris, {S. W.} and Gane, {L. W.} and Hagerman, {Paul J}",
year = "2000",
doi = "10.1002/(SICI)1096-8628(20000313)91:2<144::AID-AJMG14>3.0.CO;2-V",
language = "English (US)",
volume = "91",
pages = "144--152",
journal = "American Journal of Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical involvement and protein expression in individuals with the FMR1 premutation

AU - Tassone, Flora

AU - Hagerman, Randi J

AU - Taylor, A. K.

AU - Mills, J. B.

AU - Harris, S. W.

AU - Gane, L. W.

AU - Hagerman, Paul J

PY - 2000

Y1 - 2000

N2 - Most individuals with the fragile X premutation are clinically unaffected; however, some show clinical manifestations, including learning difficulties, emotional problems, or even mental retardation. The basis of clinical involvement in these individuals is unknown. Premutation alleles are reportedly associated with normal levels of mRNA and protein (FMRP). To examine this issue in more detail, we studied six individuals with a premutation. We are reporting these cases to demonstrate a spectrum of phenotypic involvement which can be seen clinically. These cases include one individual with the premutation who has no evidence of FMR1 gene dysfunction but has mental retardation from other causes. Other cases presented here show varying degrees of FMR1 gene dysfunction as assessed by FMRP and FMR1 mRNA levels and various clinical features of fragile X. In two cases we observed a significant reduction in FMRP expression and an elevated FMR1 mRNA expression level associated with moderate cognitive deficit. Thus, the utilization of FMRP measures can be helpful in understanding for which premutation patients clinical involvement is caused by dysfunction of the FMR1 gene. (C) 2000 Wiley-Liss, Inc.

AB - Most individuals with the fragile X premutation are clinically unaffected; however, some show clinical manifestations, including learning difficulties, emotional problems, or even mental retardation. The basis of clinical involvement in these individuals is unknown. Premutation alleles are reportedly associated with normal levels of mRNA and protein (FMRP). To examine this issue in more detail, we studied six individuals with a premutation. We are reporting these cases to demonstrate a spectrum of phenotypic involvement which can be seen clinically. These cases include one individual with the premutation who has no evidence of FMR1 gene dysfunction but has mental retardation from other causes. Other cases presented here show varying degrees of FMR1 gene dysfunction as assessed by FMRP and FMR1 mRNA levels and various clinical features of fragile X. In two cases we observed a significant reduction in FMRP expression and an elevated FMR1 mRNA expression level associated with moderate cognitive deficit. Thus, the utilization of FMRP measures can be helpful in understanding for which premutation patients clinical involvement is caused by dysfunction of the FMR1 gene. (C) 2000 Wiley-Liss, Inc.

KW - FMRP

KW - Fragile X syndrome

KW - Immunocytochemistry

KW - Mental retardation

KW - Trinucleotide repeat

UR - http://www.scopus.com/inward/record.url?scp=0034016083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034016083&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(20000313)91:2<144::AID-AJMG14>3.0.CO;2-V

DO - 10.1002/(SICI)1096-8628(20000313)91:2<144::AID-AJMG14>3.0.CO;2-V

M3 - Article

C2 - 10748416

AN - SCOPUS:0034016083

VL - 91

SP - 144

EP - 152

JO - American Journal of Medical Genetics

JF - American Journal of Medical Genetics

SN - 1552-4825

IS - 2

ER -